@genomicscow.bsky.social
Original and probably disagreeable perspectives on genomics. Not sure when I'm joking and when I'm being serious. Opinions my own, not the herd’s.
Pinned
#Genomics on social media is mainstream. Kinda boring.
Don't follow the herd
Don't follow the herd
Does the rate of X/Bluesky usage correlate with conference talks?
February 11, 2026 at 4:00 PM
Does the rate of X/Bluesky usage correlate with conference talks?
Like in politics, the middle powers of genomics might need to band together a bit more
Middle power companies are those could get bought by the super powers (Illumina, Thermo, Danaher, etc)
If they don’t meet in Davos they should at least meet in Orlando
Middle power companies are those could get bought by the super powers (Illumina, Thermo, Danaher, etc)
If they don’t meet in Davos they should at least meet in Orlando
January 27, 2026 at 4:12 PM
Like in politics, the middle powers of genomics might need to band together a bit more
Middle power companies are those could get bought by the super powers (Illumina, Thermo, Danaher, etc)
If they don’t meet in Davos they should at least meet in Orlando
Middle power companies are those could get bought by the super powers (Illumina, Thermo, Danaher, etc)
If they don’t meet in Davos they should at least meet in Orlando
Good to know society still wants us to
January 2, 2026 at 12:23 PM
Good to know society still wants us to
Instrument-free options for expanding the menu are what’s needed for vendors to survive this environment. It won’t score the revenue beats but it’ll reduce the lumpiness
Sequencing Firms Stay on Multiomics Path in 2025 Amidst Tough Funding Environment, Global Tensions
Sequencing Firms Stay on Multiomics Paths in 2025 Amidst Tough Funding Environment, Global Tensions
www.genomeweb.com
December 12, 2025 at 2:57 PM
Instrument-free options for expanding the menu are what’s needed for vendors to survive this environment. It won’t score the revenue beats but it’ll reduce the lumpiness
Job interview question: Please recite your 96 times table
December 9, 2025 at 1:45 PM
Job interview question: Please recite your 96 times table
AGBT is elitist, over-priced, demands that a written justification for my attendance, in a red state…
Woohoo I got accepted!
Woohoo I got accepted!
November 20, 2025 at 9:48 PM
AGBT is elitist, over-priced, demands that a written justification for my attendance, in a red state…
Woohoo I got accepted!
Woohoo I got accepted!
The research community often moves by methods, maybe as much as it moves by questions
Affinity approaches expands the proteomics tent. Then they will ask more granular questions that direct approaches can answer. Walk, then run, etc
Affinity approaches expands the proteomics tent. Then they will ask more granular questions that direct approaches can answer. Walk, then run, etc
November 6, 2025 at 9:11 PM
The research community often moves by methods, maybe as much as it moves by questions
Affinity approaches expands the proteomics tent. Then they will ask more granular questions that direct approaches can answer. Walk, then run, etc
Affinity approaches expands the proteomics tent. Then they will ask more granular questions that direct approaches can answer. Walk, then run, etc
I don’t disagree with your theme but in context if that quote it’s worth remembering that Pharma usually outputs antibodies to drug targets
October 26, 2025 at 8:17 PM
I don’t disagree with your theme but in context if that quote it’s worth remembering that Pharma usually outputs antibodies to drug targets
It could still be 500 slides. But presented at the speed of his brain!
September 15, 2025 at 6:09 PM
It could still be 500 slides. But presented at the speed of his brain!
What took Xenium so long to get protein panels out? These were touted several years ago
- Resources taken from Xenium?
- Resources in Xenium but needed for other features or bugs to fix?
- Chemistry was poorly optimized for dev teams to finalized?
But one answer can’t be true: lack of demand.
- Resources taken from Xenium?
- Resources in Xenium but needed for other features or bugs to fix?
- Chemistry was poorly optimized for dev teams to finalized?
But one answer can’t be true: lack of demand.
August 20, 2025 at 3:48 PM
What took Xenium so long to get protein panels out? These were touted several years ago
- Resources taken from Xenium?
- Resources in Xenium but needed for other features or bugs to fix?
- Chemistry was poorly optimized for dev teams to finalized?
But one answer can’t be true: lack of demand.
- Resources taken from Xenium?
- Resources in Xenium but needed for other features or bugs to fix?
- Chemistry was poorly optimized for dev teams to finalized?
But one answer can’t be true: lack of demand.
“Cry, the beloved country, these things are not yet at an end”
Alan Paton
Alan Paton
August 13, 2025 at 9:19 PM
“Cry, the beloved country, these things are not yet at an end”
Alan Paton
Alan Paton
Just saw that Somalogic nabbed a big win 👏
1. Big non European cohort doing proteomics 👍
2. Competition where SomaScan won 🥇
3. But now Illumina buying Somalogic to run on NGS🦈
4. But why generate this data on a microarray platform w limited future? 🤷♀️
investors.standardbio.com/news-release...
1. Big non European cohort doing proteomics 👍
2. Competition where SomaScan won 🥇
3. But now Illumina buying Somalogic to run on NGS🦈
4. But why generate this data on a microarray platform w limited future? 🤷♀️
investors.standardbio.com/news-release...
Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study | Standard BioTools Inc.
The Investor Relations website contains information about Standard BioTools Inc.'s business for stockholders, potential investors, and financial analysts.
investors.standardbio.com
August 13, 2025 at 11:57 AM
Just saw that Somalogic nabbed a big win 👏
1. Big non European cohort doing proteomics 👍
2. Competition where SomaScan won 🥇
3. But now Illumina buying Somalogic to run on NGS🦈
4. But why generate this data on a microarray platform w limited future? 🤷♀️
investors.standardbio.com/news-release...
1. Big non European cohort doing proteomics 👍
2. Competition where SomaScan won 🥇
3. But now Illumina buying Somalogic to run on NGS🦈
4. But why generate this data on a microarray platform w limited future? 🤷♀️
investors.standardbio.com/news-release...
Your users can simply choose on price/performance
July 27, 2025 at 9:54 PM
Your users can simply choose on price/performance
Regardless of the results, why would you NOT offer PIPseq as a service given not barriers to start this protocol?
July 27, 2025 at 9:53 PM
Regardless of the results, why would you NOT offer PIPseq as a service given not barriers to start this protocol?
Company posting message about how important their products are
…and backing this up with a picture of their Chief-anything-Officer with a quote about how much we should believe this
#imsold!
🐮
…and backing this up with a picture of their Chief-anything-Officer with a quote about how much we should believe this
#imsold!
🐮
July 14, 2025 at 7:49 PM
Company posting message about how important their products are
…and backing this up with a picture of their Chief-anything-Officer with a quote about how much we should believe this
#imsold!
🐮
…and backing this up with a picture of their Chief-anything-Officer with a quote about how much we should believe this
#imsold!
🐮
Now waiting for some GWAS studies followed to find cool genes, followed by analyses on how coolness is confounded by mating behavior 😎
www.nytimes.com/2025/06/30/w...
www.nytimes.com/2025/06/30/w...
What Makes Someone Cool? A New Study Offers Clues.
www.nytimes.com
July 11, 2025 at 5:48 PM
Now waiting for some GWAS studies followed to find cool genes, followed by analyses on how coolness is confounded by mating behavior 😎
www.nytimes.com/2025/06/30/w...
www.nytimes.com/2025/06/30/w...
Where illumina could struggle culturally is to do product development beyond the current somalogic kit going around. They indicate this so let’s see
June 23, 2025 at 7:19 PM
Where illumina could struggle culturally is to do product development beyond the current somalogic kit going around. They indicate this so let’s see
I think it’s an old perception that illumina reps can only sell boxes. Illumina run rate is pretty high per instruments and they are less focused on new sites but upgrading and developing business around each sequencer
June 23, 2025 at 7:18 PM
I think it’s an old perception that illumina reps can only sell boxes. Illumina run rate is pretty high per instruments and they are less focused on new sites but upgrading and developing business around each sequencer
So we will see illumina at HUPO this year?
June 23, 2025 at 5:00 PM
So we will see illumina at HUPO this year?
In all cases you already know that library prep balloons well above sequencing costs compared to classic methods illumina is already doing prep kits for
June 23, 2025 at 4:58 PM
In all cases you already know that library prep balloons well above sequencing costs compared to classic methods illumina is already doing prep kits for
Like with spatial and single cell, they don’t need to, do they? They just need a bigger slice of the library prep pie
June 23, 2025 at 4:57 PM
Like with spatial and single cell, they don’t need to, do they? They just need a bigger slice of the library prep pie
You’re a bright star in this sky. Keep posting!!
June 10, 2025 at 9:56 PM
You’re a bright star in this sky. Keep posting!!
Such timing.
Not the LinkedIn part though, that’s still boring
Not the LinkedIn part though, that’s still boring
Imagine if people were honest on LinkedIn:
Instead of congratulating someone on their new role,
“This person burned their bridges”
Till then, LinkedIn is just one big self-advertising platform
🐮
Instead of congratulating someone on their new role,
“This person burned their bridges”
Till then, LinkedIn is just one big self-advertising platform
🐮
June 6, 2025 at 6:19 PM
Such timing.
Not the LinkedIn part though, that’s still boring
Not the LinkedIn part though, that’s still boring
Call me heartless if you want, but I’m a bit jaded with this pitch:
“Someone I knew had a disease, so I started a company…”
“Someone I knew had a disease, so I started a company…”
June 6, 2025 at 9:53 AM
Call me heartless if you want, but I’m a bit jaded with this pitch:
“Someone I knew had a disease, so I started a company…”
“Someone I knew had a disease, so I started a company…”
Imagine if people were honest on LinkedIn:
Instead of congratulating someone on their new role,
“This person burned their bridges”
Till then, LinkedIn is just one big self-advertising platform
🐮
Instead of congratulating someone on their new role,
“This person burned their bridges”
Till then, LinkedIn is just one big self-advertising platform
🐮
June 4, 2025 at 5:08 PM
Imagine if people were honest on LinkedIn:
Instead of congratulating someone on their new role,
“This person burned their bridges”
Till then, LinkedIn is just one big self-advertising platform
🐮
Instead of congratulating someone on their new role,
“This person burned their bridges”
Till then, LinkedIn is just one big self-advertising platform
🐮